Introduction {#dmx011s6}
============

Endometriosis and oestrogen dependence {#dmx011s6a}
--------------------------------------

Endometriosis is a disease that affects an estimated 6--10% of reproductive aged women, totalling approximately 176 million women worldwide ([@dmx011C11]). It is defined as the presence of endometrial-like tissue in extrauterine locations and is a chronic condition associated with debilitating pelvic pain, dyspareunia, dysuria, dysmenorrhoea and infertility. However, due to a lack of reliable diagnostic tools and the non-specific nature of the symptoms, there exists a widely recognized delay in diagnosis of 8--10 years ([@dmx011C3]). Consequently, the economic impact is substantial, as chronic and debilitating pain from endometriosis may hinder work productivity, while infertility can cause major psychosocial and financial strain to affected women and their partners ([@dmx011C89], [@dmx011C88]).

The pathophysiology of endometriosis is complex and not completely understood. Sampson\'s retrograde menstruation theory, which states that endometrial cells travel backwards through the fallopian tubes during menses to reach the peritoneal cavity, has gathered the most robust support ([@dmx011C101]). Oestrogen dependence, progesterone resistance, inflammation and genetic predisposition represent some of the pathophysiological hallmarks of this disease ([@dmx011C13]). The central feature is oestrogen-dependent growth. Endometriotic lesions pathologically overexpress oestrogen receptor beta (ERβ) (\>100× higher expression compared to endometrial tissue) and have been demonstrated to express (i) high levels of steroidogenic acute regulatory protein (StAR) and P450 aromatase, and (ii) reduced levels of 17beta hydroxysteroid dehydrogenase Type 2. This expression profile results in locally elevated levels of the biologically active form of oestrogen (oestradiol) ([@dmx011C49]; [@dmx011C12]). These molecular studies are supported by clinical observations of disease regression, symptom relief and alleged 'cures' for endometriosis as women achieve a hypo-oestrogenic state through iatrogenic or natural menopause ([@dmx011C41]).

Transition to menopause {#dmx011s6b}
-----------------------

Understanding the altered hormonal milieu in endometriosis has enabled clinicians to exploit oestrogen dependence in their management, prescribing medications to suppress ovarian function or alter local oestrogenic effects. However, in severely symptomatic cases, first-line medical therapy (including the oral contraceptive pill or progestogens) or laparoscopic excision of endometriotic lesions may prove insufficient, and induction of menopause via GnRH analogues or oophorectomy is indicated ([@dmx011C25]). Surgically or medically induced menopause is associated with a swift and dramatic fall in oestrogen levels. This decline may relieve endometriosis-related symptoms, but can simultaneously trigger menopausal symptoms. These symptoms are diverse and include hot flushes, vaginal dryness, sleep and mood disturbances, night sweats and painful intercourse, among others. While these symptoms occur in many women who naturally transition into menopause, they are especially prevalent and severe in women with a sudden onset of the hypoestrogenic state ([@dmx011C37]). The gold standard for treatment of menopausal symptoms has traditionally been hormone replacement therapy (HRT). HRT has been crucial for achieving symptom relief and improving the quality of life of millions of menopausal women, although these successes have been accompanied by safety concerns regarding specific preparations and dosages ([@dmx011C54]).

Appropriateness of HRT {#dmx011s6c}
----------------------

Many studies have explored the efficacy and safety of HRT in postmenopausal women with climacteric symptoms ([@dmx011C82]; [@dmx011C84]); however, few studies have investigated the use of hormonal therapy in postmenopausal women with a history of endometriosis. Two specific concerns are present in this group of women. Firstly, there is the possibility that exogenous oestrogen will reactivate growth of endometriotic deposits and cause symptomatic recurrence. Secondly, there is a concern that oestrogen will promote malignant transformation of residual endometriotic tissue. Sampson first described malignant transformation of ovarian endometriosis in 1925 ([@dmx011C85]) and although its pathogenesis is not fully understood, oxidative stress, inflammation and an altered hormonal milieu have been implicated as contributing factors ([@dmx011C66]). Malignant transformation is thought to be a multistep pathway in which normal endometriotic tissue progresses to an atypical intermediate stage, and finally to invasive carcinoma ([@dmx011C30]). These sequential steps towards malignancy have been associated with genetic alternations in PTEN, TP53 and ARID1A and have been demonstrated in endometriosis-associated cancers ([@dmx011C65]). In a recent animal study using a rodent model of endometriosis (adult female Sprague-Dawley rats, aged 8--12 weeks), treatment with unopposed oestrogen successfully induced malignant transformation of endometriotic foci ([@dmx011C103]). Mechanistically, oestrogens affect PTEN expression in human endometrial cells and are associated with increased proliferation, direct cell damage and increased risk of acquiring somatic mutations ([@dmx011C100]).

However, the impact of declining oestrogen levels should not be underestimated. Menopausal symptoms affect the lives of millions of women worldwide. The hypo-oestrogenic state can significantly impair the quality of life by making sexual intercourse uncomfortable or painful, causing sleep deprivation, or resulting in mood changes. Furthermore, declining systemic oestrogen levels are a risk factor for cardiovascular and bone disease ([@dmx011C31]; [@dmx011C81]). The use of HRT has been shown to reduce the risk of such conditions and improve the quality of life of symptomatic women ([@dmx011C52]).

The decision whether or not to prescribe HRT in general, and particularly in women with a history of endometriosis, is therefore a complex clinical decision and may also take into account other risk factors, such as residual disease after surgery ([@dmx011C20]) and obesity which causes increased aromatase activity in peripheral tissues resulting in higher systemic oestrogen levels ([@dmx011C106]).

Our study aimed to conduct a systematic review of the literature investigating a critical question: What is the current evidence on the management of menopausal symptoms in women with a history of endometriosis? We aimed to cover the literature on a number of sub-questions, including: What are the various treatment options to manage menopausal symptoms in these women? What are the risks associated with HRT in this cohort? Should HRT be given immediately following surgically induced menopause or be delayed? What preparations are most appropriate, and for how long should treatment be given? We aimed to synthesize the literature in a comprehensive manner, and hoped to aid the design of future research in this area. Given the prevalence of endometriosis and the inevitability of eventual menopause in these women, this is clearly an important question that warrants robust, evidence-based guidelines.

Methods {#dmx011s7}
=======

This systematic review was registered and accepted for inclusion in PROSPERO ([@dmx011C32]) in July 2016 (PROSPERO ID number: CRD42016042024).

Search strategy {#dmx011s7a}
---------------

We searched four electronic databases (MEDLINE via OVID, Embase via OVID, PsycINFO via OVID and CINAHL via EbscoHost), from database inception until 26 June 2016, using a combination of relevant controlled vocabulary terms and free-text terms searched in the title or abstract fields related to 'menopause' and 'endometriosis'. No study type, language or date limits were applied to the search. An example of the search strategy used for the MEDLINE database is included in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Inclusion criteria {#dmx011s7b}
------------------

All retrieved studies were uploaded to EndNote and duplicates were deleted. One reviewer (L.G.) sifted the full library (titles/abstracts), and two reviewers (K.W., C.B.) sifted 10% of the library (randomly selected using EndNote Record Number) to assess concordance. The full text of potentially relevant articles was retrieved to assess whether the paper should be included. Inclusion criteria were that the study population included postmenopausal women with a confirmed, or clinically suspected, history of endometriosis, and the article discussed management of menopausal symptoms. All study designs were included (case reports, observational studies and clinical trials). We excluded articles that did not discuss any form of menopausal management (e.g. HRT, tibolone or other preparations). We excluded narrative review articles and organizational guidelines in an attempt to focus the review on primary literature. Conference abstracts were also excluded.

The reviewers shared their lists of included studies, and concordance was determined. When there were disparities in the list, consensus was reached through discussions between the reviewers.

Quality assessment {#dmx011s7c}
------------------

Quality of included studies was assessed independently by two reviewers (L.G., K.W.) using the GRADE criteria ([@dmx011C35]). Assigned ratings were compared and a third reviewer (C.B.) was consulted when there were disagreements.

Data extraction {#dmx011s7d}
---------------

Data were extracted into a standard form by one reviewer (L.G). For case reports, the following information was extracted: patient age at presentation, presenting symptoms, ureteral involvement (yes or no), type (surgical vs. natural) and timing (years previously) of menopause, stage and extent of endometriosis before menopause, reported menopausal symptoms, treatment provided, duration of follow-up, method of outcome assessment, outcome (recurrence, malignant transformation, side effects, mortality) and recommendation (if provided).

For all other study types, information on study design, study objective, sample size, participants' characteristics, intervention, method of outcome assessment, outcome, duration of follow-up and recommendation (if provided) was recorded.

Data synthesis and analysis {#dmx011s7e}
---------------------------

The nature of the evidence retrieved by our search (predominantly case reports, and a small number of heterogeneous observational studies and clinical trials) meant that meta-analysis was not possible, thus a narrative synthesis of the data is provided.

Where possible, if not reported in the original article, risk ratios (RRs) for specific outcomes were calculated using RevMan ([@dmx011C78]).

Results {#dmx011s8}
=======

Included studies {#dmx011s8a}
----------------

Searches across all four databases retrieved 17 488 studies. Duplicates (5008) were removed, leaving 12 480 studies (Fig. [1](#dmx011F1){ref-type="fig"}). After reading titles and abstracts, 12 366 failed to meet inclusion criteria. The full-text versions of the remaining 114 studies were read in their entirety. Of these 114 studies, 75 were excluded because they did not meet our inclusion criteria. This left 39 included studies: 33 case reports and 6 observational studies and clinical trials.

![Flow diagram depicting inclusion and exclusion decisions throughout the review process.](dmx011f01){#dmx011F1}

The majority of relevant articles identified by the search were individual case reports or case series describing the recurrence of endometriosis or malignant transformation in postmenopausal women. A small number of observational studies and clinical trials were also identified. We first present a summary of the data from case reports and case series to give context, before describing the results of the observational cohorts and trials.

Case reports and case series (33 studies; 48 patients) {#dmx011s8b}
------------------------------------------------------

There were 32 case reports/series including 42 patients identified by our search. An additional article describing endometriosis-related malignancies in six women who had taken oestrogen replacement was retrieved ([@dmx011C53]). This article is discussed separately, as insufficient data are reported for the individual women to enable inclusion in our summary statistics.

Outcome evidence provided by these reports was assessed as very low quality given their observational nature and inherent risk of publication bias. Summary characteristics of the 42 patients are presented in Table [I](#dmx011TB1){ref-type="table"}. The age of included patients ranged between 30 and 75 years at presentation (mean age: 52 years). Of 42 patients, 40 had prior histories of endometriosis, either (i) confirmed by intraoperative visualization and/or histologically after laparoscopic excision (*n* = 34), (ii) suspected given the presence of symptoms (infertility, pelvic pain, menorrhagia) (*n* = 2), or (iii) assessed by unspecified methodology (*n* = 4). Two patients did not have premenopausal endometriosis diagnoses, but were speculated by the case report authors to have had such and are thus included in our analysis. There were 36 patients who went through a surgically induced menopause (procedures involving oophorectomy), and four patients went through menopause naturally (one of these four was diagnosed with premature ovarian insufficiency). An additional two patients are believed to have gone through natural menopause, and underwent oophorectomy at ages 57 and 60. HRT was given as treatment for (*n* = 12) or prevention of (*n* = 30) menopausal symptoms. The mean duration of HRT use prior to presentation was 7.8 years (range: 4 months to 20 years). Of 36 patients who had undergone hysterectomy, 31 used unopposed oestrogen therapy. Table ISummary characteristics from case reports and series.Case reports and series (GRADE ([@dmx011C35]) scoring: very low quality)Number of patients (*n*)42Age range (years) (mean (years))30--75 (52)Type of menopause (*n*)Surgical: 36Natural: 4Presumed natural + oophorectomy later: 2Mean duration of HRT (years)7.8Unopposed oestrogen (*n*)31Endometriosis recurrence (*n*)17Malignant transformation (*n*)25Mortality (*n*)3

The two main outcomes reported were endometriosis recurrence (*n* = 17) and malignant transformation (*n* = 25). For analysis, case reports and series were divided by these two main outcomes. One case series was included in both outcomes as it described three patients with endometriosis recurrence and one patient with malignant transformation ([@dmx011C98]).

Endometriosis recurrence in women on HRT (17 patients) {#dmx011s8c}
------------------------------------------------------

Thirteen case reports and case series were identified reporting endometriosis recurrence in menopausal women given HRT for the treatment or prevention of menopausal symptoms. These included 17 patients between the ages of 30--65 (median age: 46 years) (Table [II](#dmx011TB2){ref-type="table"}). All of the included women had undergone treatment with exogenous oestrogens in some form. [@dmx011C91] was the earliest report retrieved by our search. This case was a 48-year-old Caucasian woman who presented with a 2-month history of painless haematuria and decreased urinary stream on voiding. She had undergone a total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH + BSO) with endometriosis found in the specimen and confirmed by histology. She had been prescribed conjugated oestrogens (Premarin 1.25 mg/day) following surgery and continued these for 6 years until her presentation. On physical examination, a 7 cm × 8 cm mass starting in the midline and extending to the left pelvic wall was palpated and the patient underwent cystoscopy. Postmenopausal bladder endometriosis was diagnosed histologically. Oestrogens were discontinued and intramuscular medroxyprogesterone acetate (1 gm per week) was administered for 2 months. Despite this, there was no significant alteration in the size of the mass. Shortly afterwards, due to symptom recurrence, the endometriotic lesion was removed surgically. The patient had no complaints 1-year post treatment. The authors commented that exogenous oestrogens play a role in the stimulation and development of postmenopausal endometriosis. Table IICase reports and series reporting the postmenopausal recurrence of endometriosis after HRT in women with a history of endometriosis.Author, date (\# patients)Patient Age (years)Presenting symptoms \[ureter involvement\]Medical history and menopauseHRT \[duration\]DiagnosisTreatment \[follow-up: patient status\][@dmx011C91](*N* = 1)48Painless haematuria + palpable bladder mass \[No\]EndometriosisSurgical menopauseOestrogen-only HRTConjugated oestrogen tablets \[6 years\]Postmenopausal bladder endometriosisDiscontinued oestrogens + initiated Depo-Provera + surgery \[1 year: no complaints\][@dmx011C94](*N* = 1)65Intermittent painless haematuria \[No\]Leiomyoma, no confirmed history of endometriosis, but speculated by authorsUnclear menopause (underwent TAH + right SO at age 59)Oestrogen-only HRTOestrogen tablets \[3 years\]Bladder endometriosis extending into bowelSurgery \[6 weeks: cystoscopy revealed normal appearing bladder and bimanual examination was normal\][@dmx011C46](*N* = 1)56Painless haematuria; two episodes of gross haematuria 10 days before admission \[Yes\]Uterine leiomyomas, bilateral endometriomas, right fallopian tube endometriosisSurgical menopauseOestrogen-only HRTConjugated oestrogen tablets \['long term'\]Postmenopausal ureteral endometriosisSurgery \[18 months: no complaints\][@dmx011C76](*N* = 1)64Painless haematuria \[Yes\]Right ovarian endometriosisSurgical menopauseOestrogen-only HRTConjugated oestrogen tablets \[13 years\]Ureteral obstruction secondary to adenomatous hyperplasia arising in endometriosisSurgery \[Not specified\][@dmx011C55](*N* = 2)4739Three day history of vomiting and right iliac fossa pain \[Yes\]Two day history of severe left loin and left iliac fossa pain \[Yes\]Bilateral ovarian endometriosisExtensive endometriosisBoth surgical menopauseOestrogen-only HRTOestradiol implant, ethinyloestradiol \[5 years, 3 days 2 weeks prior to presentation\]Oestradiol implant \[9 years\]Large chocolate cyst (3 cm in diameter) compressing ureter at bifurcation of iliac vesselChocolate cyst (3--4 cm in diameter), endometriosis in the cyst wall and end-stage obstructive uropathy of the kidneySurgery \[2 years: no complaints, on Danazol\]Surgery \[6 months: no complaints, on Danazol\][@dmx011C34](*N* = 1)545-month history of left iliac fossa pain, especially during her monthly withdrawal bleeding \[No\]Endometriosis suggested by symptoms: primary infertility and recurrent left iliac fossa painNatural menopauseCombined HRTConjugated oestrogen tablets + oral medroxyprogesterone \[1 year\]8 cm left ovarian endometrioma adherent to sigmoid colon---uterus had extensive endometrial deposits on serosal surfaceSurgery \[2 years: no complaints, on Premarin to treat menopausal symptoms\][@dmx011C45](*N* = 1)30Recurrent haemoptysis and left-sided haemothorax \[No\]Extensive pelvic endometriosis, pleural endometriosisSurgical menopauseCombined HRTOestrogen and progesterone \[4 months\]Recurrent thoracic endometriosisSurgery \[9 months: no complaints, advised to delay HRT\][@dmx011C98](*N* = 3)424038Left abdominal pain and vaginal bleeding \[Yes\]Severe lower abdominal pain \[No\]Severe dyspareunia \[No\]All had severe or extensive endometriosisAll surgical menopauseOestrogen-only HRTAll used oestradiol implants\[3 years\]\[2 years\]\[2 years\]Endometriotic mass in left pelvis obstructing ureterExtensive pelvic endometriosisEndometriosis of vaginal vaultSurgery \[6 years: no complaints, on continuous combined hormone replacement\]Surgery + discontinued oestradiol implant \[Not specified\]Surgery \[Not specified, on tibolone\][@dmx011C8](*N* = 2)3540Vaginal bleeding that intensified and became constant, severe cramping \[No\]Worsening vaginal bleeding of several months duration \[No\]Severe chronic pelvic pain, dyspareunia, dysmenorrhoea, bilateral ovarian endometriosisSevere endometriosis, right ovarian endometriosis, adenomyosisBoth surgical menopauseOestrogen-only HRT and combined HRTOestrogen patch followed by 'various regiments of oestrogen and progestogen' \[3 months, 1 year\]Oestrogen patch \[19 months\]Both---endocervical endometriosisSurgery \[Not specified\]Surgery \[Not specified, on ERT\][@dmx011C97](*N* = 1)46Haematuria and rectal bleeding \[No\]EndometriosisSurgical menopauseOestrogen-only HRTOestradiol implants, followed by oestradiol patches \[Not specified, but patient stopped HRT 12 months prior to presentation\]5 cm endometriotic nodule in the sigmoid that was adherent to the bladder; florid endometriosis with polypoid endometrial mucosal lesions with vascular invasion involving both bowel and bladderSurgery \[Not specified\][@dmx011C15](*N* = 1)463 episodes of haemoptysis synchronous on 1st day of menstrual cycle \[Unknown\]Endometriosis suspected by symptoms: menorrhagiaNatural menopauseCombined HRTOestradiol + cyproterone \[3 years\]Catamenial haemoptysis due to endobronchial endometriosisTerlipressin + Discontinued HRT \[2 years: no complaints\][@dmx011C57](*N* = 1)49Asymptomatic pelvic mass detected during routine examination \[No\]Pelvic endometriosis associated with infertility and adhesionsPremature ovarian insufficiencyCombined HRTConjugated equine oestrogens + norethisterone \[7 years\]Intestinal endometriosis presenting as a pedunculated endometriomaTibolone + Surgery \[Not specified\][@dmx011C33](*N* = 1)44Painless vaginal bleeding for 4 weeks \[Yes\]Endometriosis and infertilitySurgical menopauseOestrogen-only HRTConjugated oestrogen \[10 years\]Endometriotic mass (8 × 7 × 6.5) involving the vaginal mucosa and invading into the rectal wallSurgery \[3 months: uneventful recovery and ileostomy was closed\][^1]

Sixteen other similar accounts were retrieved from our search, with the latest report published in 2009 ([@dmx011C33]). The majority of cases (12 out of 17) were women with a prior hysterectomy, who took unopposed oestrogen. The remaining cases of recurrence were in women who took combined HRT.

### Severity of prior endometriosis and menopause {#dmx011s8c_1}

Six patients had a history of 'extensive' or 'severe' endometriosis ([@dmx011C55]; [@dmx011C45]; [@dmx011C98]; [@dmx011C8]). Fourteen patients underwent surgical menopause years before presentation ([@dmx011C91]; [@dmx011C94]; [@dmx011C46]; [@dmx011C76]; [@dmx011C55]; [@dmx011C45]; [@dmx011C98], [@dmx011C97]; [@dmx011C8]; [@dmx011C33]), while only two transitioned naturally to menopause ([@dmx011C34]; [@dmx011C15]). One patient entered menopause as a result of premature ovarian insufficiency ([@dmx011C57]). The median time between surgical menopause and presentation was 7.1 years (range: 4 months to 13 years).

### Menopausal management {#dmx011s8c_2}

Unopposed oestrogen was implicated in numerous cases of symptom recurrence (*n* = 12) ([@dmx011C91]; [@dmx011C94]; [@dmx011C46]; [@dmx011C76]; [@dmx011C55]; [@dmx011C98], [@dmx011C97]; [@dmx011C8]; [@dmx011C33]). Fewer studies reported recurrence in women who were using combined hormonal preparations (oestrogen and progestagen) (*n* = 5) ([@dmx011C34]; [@dmx011C45]; [@dmx011C8]; [@dmx011C15]; [@dmx011C57]). In terms of method of oestrogen administration, oral tablets (*n* = 5) ([@dmx011C91]; [@dmx011C94]; [@dmx011C46]; [@dmx011C76]; [@dmx011C34]), implants (*n* = 6) ([@dmx011C55]; [@dmx011C98], [@dmx011C97]) and patches (*n* = 3) ([@dmx011C8]; [@dmx011C97]) were all reported. Table [III](#dmx011TB3){ref-type="table"} provides information on HRT dosages and regimens; however, variability in the level of detail provided by the included case reports and series limits these data. Table IIIHRT dosages and regimens associated with recurrent endometriosis in case reports and series.HRT typeDosages and regimens associated with recurrent postmenopausal endometriosis (*n* = 17 patients)Oestrogen-only1. Premarin 1.25 mg/day ([@dmx011C91])2. Premarin ([@dmx011C46])3. Oestrogens 2.5 mg/day ([@dmx011C76])4. 2.5 mg oestrogen/day, but taking twice the recommended dose ([@dmx011C94])5. Oestrogen patch 0.05 mg twice a week ([@dmx011C8])6. Conjugated oestrogen 1.25 mg/day ([@dmx011C33])7. Oestradiol implant 100 mg 6 monthly for 5 years, subsequent 2 years of taking no hormones, then 2 weeks before admission felt run down and took three 10 μg tablets of ethinyloestradiol on consecutive days ([@dmx011C55])8. 100 mg oestradiol annual hormone implants ([@dmx011C55])9. Oestradiol implant ([@dmx011C98])10. Oestradiol implant ([@dmx011C98])11. Oestradiol implant ([@dmx011C98])12. First oestradiol implant, then Evorel 50 patches ([@dmx011C97])Combined13. Conjugated equine oestrogens 625 mcg, norethisterone 150 mcg cyclically ([@dmx011C57])14. Premarin 0.625 mg daily and Provera 10 mg daily for 12 days a month ([@dmx011C34])15. Oestrogen + progesterone ([@dmx011C45])16. Oestrogen patch 0.05 mg weekly followed by various regimens of oestrogen and progestogen ([@dmx011C8])17. Oestradiol and cyproterone ([@dmx011C15])

### Presenting symptoms and sites of recurrence {#dmx011s8c_3}

As may be expected, endometriosis recurrence commonly presented with pain (*n* = 7): in locations typical of premenopausal endometriosis, i.e. abdomen ([@dmx011C98]), iliac fossae ([@dmx011C55]; [@dmx011C34]), genitals ([@dmx011C98]); and in more unusual sites such as the loin ([@dmx011C55]). Abnormal bleeding was also a common presentation (*n* = 14), including postmenopausal vaginal bleeding ([@dmx011C98]; [@dmx011C8]; [@dmx011C33]), haematuria ([@dmx011C91]; [@dmx011C94]; [@dmx011C46]; [@dmx011C76]; [@dmx011C97]), rectal bleeding ([@dmx011C97]) and also haemoptysis ([@dmx011C45]; [@dmx011C15]). Two women were reported to have pelvic masses ([@dmx011C91]; [@dmx011C57]).

Sites of recurrence included: the genitourinary tract (*n* = 14), i.e. bladder ([@dmx011C91]; [@dmx011C94]; [@dmx011C97]), ureter ([@dmx011C46]; [@dmx011C76]; [@dmx011C55]; [@dmx011C98]; [@dmx011C33]), ovary ([@dmx011C34]), cervix ([@dmx011C8]), vagina ([@dmx011C98]; [@dmx011C33]); gastrointestinal organs (*n* = 4), i.e. the bowel ([@dmx011C94]; [@dmx011C97]; [@dmx011C57]) and rectum ([@dmx011C33]); and the pulmonary system (*n* = 2) including the lung ([@dmx011C45]) and bronchus ([@dmx011C15]). [@dmx011C57] reported an unusual presentation involving an ovarian endometriotic cyst adherent to the small bowel with a solitary vascular pedicle ([@dmx011C57]). The authors hypothesized spillage during previous surgery and reactivation with hormonal therapy was responsible for this presentation.

### Management of postmenopausal endometriosis recurrence {#dmx011s8c_4}

Management was tailored to location and extent of recurrence. All cases, except for one ([@dmx011C15]), required surgical excision of endometriotic tissue. Some patients required additional medical therapy involving Depo-Provera ([@dmx011C91]), Danazol ([@dmx011C55]) and Tibolone ([@dmx011C98]; [@dmx011C57]). Three patients resumed HRT after surgery ([@dmx011C34]; [@dmx011C98]; [@dmx011C8]), two of whom were prescribed oestrogen-only formulations ([@dmx011C34]; [@dmx011C8]).

Outcomes were generally favourable, although reporting bias may have contributed to this finding. All patients with reported follow-up (range: immediate postoperative checks to 2 years post treatment) experienced symptom regression with no relapses in the follow-up period ([@dmx011C91]; [@dmx011C94]; [@dmx011C46]; [@dmx011C55]; [@dmx011C34]; [@dmx011C45]; [@dmx011C98]; [@dmx011C15]; [@dmx011C33]).

Malignant transformation (25 patients) {#dmx011s8d}
--------------------------------------

Twenty case reports and series of malignant transformation of endometriotic foci in postmenopausal women with a history of endometriosis on HRT were identified. This included a total of 25 patients between the ages of 38 and 75 years old (mean: 56 years) (Table [IV](#dmx011TB4){ref-type="table"}). An additional study by [@dmx011C53] ([@dmx011C53]) detailing the malignant transformation of endometriosis in six postmenopausal women on oestrogen-only HRT (mean duration: 23.4 years) is included in Table [IV](#dmx011TB4){ref-type="table"}, but will be discussed separately. Table IVCase reports and series reporting malignant transformation of endometriotic foci after HRT in women with a history of endometriosis.Author, date (\# patients)Patient age (years)Presenting symptoms \[ureter involvement\]Medical history and menopauseHRT \[duration\]DiagnosisTreatment \[follow-up: patient status\][@dmx011C10](*N* = 1)48Mild right-sided lower abdominal pain, urinary frequency, constipation for 2 months \[No\]Pelvic endometriosis, left ovarian endometriosis, adenomyosis, leiomyomasSurgical menopauseOestrogen-only HRTConjugated oestrogen tablets \[4 years\]Clear cell carcinoma arising in endometriosis of the retroperitoneumSurgery + radiation \[22 months: no evidence of disease\][@dmx011C50](*N* = 1)66Light vaginal bleeding \[No\]Genital endometriosisNatural menopause + TAH/BSO 6 years before presentationOestrogen-only HRTConjugated oestrogen tablets \[12 years\]Endometrioid carcinoma arising in an endometriotic lesion of the cul-de-sacSurgery \[Unclear\][@dmx011C77](*N* = 2)5847Vaginal bleeding and left flank pain \[Yes\]Nausea, vomiting, fever and flank pain \[Yes\](1) Extensive endometriosis and leiomyomataSurgical menopause(2) Extensive pelvic endometriosisSurgical menopauseBoth oestrogen-only HRT Both conjugated oestrogen tablets\[12 years\]\[4 years\]Extra-ovarian endometrioid carcinoma arising in foci of endometriosisAdenocarcinoma + adenosquamous carcinoma arising in foci of endometriosis 3 months laterSurgery + progestin therapy \[60 months: no evidence of disease\]Surgery + progestin therapy + radiation + chemotherapy \[11 months: patient deceased\][@dmx011C26](*N* = 1)62Pelvic mass \[No\]Severe endometriosis (both ovaries and extensions deep into the rectovaginal septum)Surgical menopauseOestrogen-only HRTIntramuscular oestrogen injections \[20 years\]Endometrioid adenocarcioma (extraluminal rectosigmoid tumour 10 cm in diameter and closely adherent to the bladder)Surgery + radiation \[6 weeks: patient deceased\][@dmx011C1](*N* = 1)38Intermittent vaginal bleeding of 8 weeks duration, ulcerated area over vaginal vault, polyp-like lesion on vaginal vault found 4 weeks later \[No\]Severe endometriosis involving both ovaries, adenomyosis of the uterus, chronic cervicitisSurgical menopauseOestrogen-only and combined HRTEthinyloestradiol tablets \[Not specified\]Levonorgestrel/ethinyloestradiol tablets \[Not specified\]Oestradiol implants \[Not specified\]Endometrial adenocarcinoma arising from an endometriotic focusNeoadjuvant progestin therapy + surgery + radiation \[Not specified\][@dmx011C98](*N* = 1)42Massive ascites, 6L drained \[No\]Severe endometriosisSurgical menopauseOestrogen-only HRTOestradiol implants \[7 years\]Endometroid adenocarcinomaSurgery + chemotherapy \[24 months: no evidence of disease\][@dmx011C42](*N* = 1)48Right flank discomfort \[Yes\]Endometriotic ovarian cystSurgical menopauseOestrogen-only HRTConjugated oestrogen tablets \[5 years\]Adenosquamous endometrioid carcinoma arising from disseminated pelvic endometriosisSurgery \[Not specified\][@dmx011C71](*N* = 1)56Lower abdominal pain, dyspareunia, pain with bowel movements, hirsutism \[Yes\]Extensive pelvic adhesions, peritoneal endometriosis, left ovarian endometrioma, adenomyosis, multiple leiomyomasSurgical menopauseOestrogen-only HRT and combined HRTConjugated oestrogen tablets \[10 years\]Medroxyprogesterone tablets \[3 years\]Androgen-producing endometrioid tumour of low malignant potential (borderline tumour) arising in endometriosis in the rectovaginal septumSurgery + chemotherapy + progestin therapy \[9 months: no evidence of disease\][@dmx011C44](*N* = 1)52Rectal bleeding and polyp arising from sigmoid colon \[Yes\]Deeply infiltrating rectovaginal endometriosisSurgical menopauseOestrogen-only HRTOestradiol implants \[12 years\]Well-differentiated endometrial adenocarcinoma arising from endometriosis of the rectosigmoid colonSurgery \[9 months: no evidence of disease\][@dmx011C63](*N* = 1)57Right lower-quadrant pain, recurrent macroscopic haematuria and weight loss of 8 kg in 3 months \[Yes\]Uterine fibroids and right-sided endometriomaSurgical menopause (left ovary and fallopian tube left intact)Oestrogen-only HRTOestradiol \['many years'\]Tubulopapillary endometrioid adenocarcinoma involving blood vesselsSurgery + radiation \[18 months: no evidence of disease\][@dmx011C70](*N* = 2)6157Diarrhoea, right buttock pain, rectal mass \[No\]Lower abdominal pain, rectal mass \[No\](1) EndometriosisSurgical menopause(2) Endometriotic foci on uterus, haemorrhagic endometriotic ovarian cystSurgical menopauseOestrogen-only HRT \[5 years\]HRT \[8 years\]Poorly differentiated endometrioid adenocarcinoma of the large intestine arising in colorectal endometriosisVariably differentiated endometrioid adenocarcinomaSurgery \[28 months: no evidence of disease\]Surgery \[18 months: no evidence of disease\][@dmx011C53]^[a](#dmx011tfn2){ref-type="fn"}^(*N* = 10)54.9 (mean)Not reportedNot reportedSurgical menopause (*n* = 8)Oestrogen-only HRT (*n* = 6) \[23.4 years (mean), 10--32 years (range)\]Endometrioid (*n* = 5)Adenosquamous (*n* = 2)Papillary adenocarcinoma (*n* = 1)Adenocarcinoma not otherwise specified (*n* = 2)Surgery, chemotherapy, radiation \[26 months (mean): 70% survival\][@dmx011C93](*N* = 2)6051Heavy, painless vaginal bleeding, palpable fixed mass, polypoid necrotic lesion \[Yes\]Painless mass in the right side of abdomen and several episodes of vaginal bleeding \[Yes\]1) Pelvic endometriosis, microinvasive squamous carcinoma of the cervix, leiomyomaMenopause not specified (surgical menopause at age 57)2) Extensive endometriosis involving the uterosacral ligaments, endometriotic right ovarian cystSurgical menopause (left ovary and Fallopian tube left intact)1) Oestrogen-only HRTConjugated equine oestrogen tablets \[3 years\]2) Combined HRTOestrogen and testosterone implants \[10 years\]Moderately differentiated endometrial adenocarcinomaEndometrioid adenocarcinoma arising in an endometriotic cyst within the vaginal vaultSurgery and radiation \[48 months: no evidence of disease\]Surgery \[24 months: no further tumour growth\][@dmx011C6](*N* = 1)53Abnormal vaginal bleeding for 2 months \[Yes\]Leiomyomata, endometrioid foci especially in Fallopian tubesSurgical menopauseOestrogen-only HRTOestradiol \[6 years\]Endometrioid adenocarcinoma affecting the vagina, bladder and rectumSurgery + chemotherapy \[6 months: no evidence of disease\][@dmx011C48](*N* = 1)62Abdominal mass \[No\]Infiltrating pelvic endometriosis, leiomyomaSurgical menopauseOestrogen-only HRTConjugated oestrogen tablets \[14 years\]Endometrioid adenocarcinoma arising from endometriosis of the mesocolonSurgery + chemotherapy \[28 months: no evidence of disease\][@dmx011C67](*N* = 1)75Chronic abdominal pain for 2 months, left pyelonephritis \[Yes\]Extensive endometriosis and adenomyosisSurgical menopauseOestrogen-only HRTSuper concentrated phytoestrogen supplements \[5 years\]Ureteral malignant mullerian carcinosarcoma in a context of florid endometriosisSurgery + aromatase inhibitor \[3 months: no evidence of disease\][@dmx011C60](*N* = 1)47Persistent and enlarging right groin mass, right lower-quadrant tenderness \[No\]Recurrent endometriosis, left and right endometriomasSurgical menopauseOestrogen-only HRTOestrogen tablets \[16 years\]Adenosarcoma arising in endometriosisSurgery \[12 months: no evidence of disease\][@dmx011C5](*N* = 1)68Left-sided pelvic mass, shortness of breath \[No\]Endometriosis and multiple large fibroidsSurgical menopauseOestrogen-only HRT \[13 years\]Metastatic endometrioid adenocarcinomaChemotherapy \[24 months: patient is alive and well\][@dmx011C19](*N* = 1)66Abdominal/pelvic pain and mass, alteration of general state, 10 kg weight loss, constipation, dysuria \[Yes\]Never had endometriosis-specified pain, but unclear whether patient had endometriosisNatural menopauseCombined HRTOestradiol and medroxyprogesterone acetate \[11 years\]Extragenital endometrioid carcinoma in the vesico-uterine pouch arising from endometriosisSurgery + chemotherapy + radiation \[8 months: patient deceased\][@dmx011C27](*N* = 1)598-week history of constipation, tenesmus, 7 kg weight loss \[No\]Severe ovarian endometriosis and in floor of pelvisSurgical menopauseCombined HRTOestradiol and testosterone implant \[13 years\]Well-demarcated, cystic, endometrioid adenocarcinoma (endometriosis-associated intestinal tumour)Surgery \[Not specified\][@dmx011C47](*N* = 3)605655Intermittent right-sided abdominal pain for 4 years \[Yes\]Recent onset of discomfort in her right iliac fossa \[No\]Cramp-like discomfort in the abdomen and thighs and postmenopausal bleeding \[No\]1) Ovarian endometriosis and adenomyosisSurgical menopause2) Widespread endometriosis in the ovary, uterine serosa and bowelSurgical menopause3) Endometriosis and left ovarian endometriomaSurgical menopause1) Oestrogen-only HRTOestrogen implants \[14 years, discontinued 8 years before presentation\]2) Combined HRTOestradiol and testosterone implants \[12 years, discontinued 4 years before presentation\]3) Combined HRTOestrogen and testosterone implants \[9 years\]Adenosarcoma with heterologous leiomyosarcomatous element and moderately differentiated endometrioid adenocarcinomaEndometrioid adenocarcinomaHigh grade endometrial stromal sarcoma arising in residual foci of endometriosis and infiltrating the bowelSurgery + aromatase inhibitor + chemotherapySurgery + chemotherapySurgery + chemotherapy\[All cases were still being treated at the time of publication\][^2][^3]

### Severity of prior endometriosis {#dmx011s8d_1}

About 13 patients had medical histories that noted endometriosis in more than one site ([@dmx011C10]; [@dmx011C26]; [@dmx011C1]; [@dmx011C71]; [@dmx011C44]; [@dmx011C70]; [@dmx011C93]; [@dmx011C60]; [@dmx011C67]; [@dmx011C27]; [@dmx011C47]), and 13 patients had histories of ovarian endometriosis ([@dmx011C10]; [@dmx011C26]; [@dmx011C1]; [@dmx011C42]; [@dmx011C71]; [@dmx011C63]; [@dmx011C70]; [@dmx011C93]; [@dmx011C60]; [@dmx011C27]; [@dmx011C47]). Some histories specified 'severe endometriosis' (*n* = 4) ([@dmx011C26]; [@dmx011C1]; [@dmx011C98]; [@dmx011C27]), while others reported 'extensive endometriosis' (*n* = 4) ([@dmx011C77]; [@dmx011C93]; [@dmx011C67]). Some histories included comorbidities such as leiomyomas (*n* = 6) ([@dmx011C10]; [@dmx011C77]; [@dmx011C71]; [@dmx011C6]; [@dmx011C93]; [@dmx011C48]) and adenomyosis (*n* = 5) ([@dmx011C10]; [@dmx011C1]; [@dmx011C71]; [@dmx011C67]; [@dmx011C47]). Patients typically underwent surgical menopause (*n* = 22) ([@dmx011C10]; [@dmx011C77]; [@dmx011C26]; [@dmx011C1]; [@dmx011C98]; [@dmx011C42]; [@dmx011C71]; [@dmx011C44]; [@dmx011C63]; [@dmx011C70]; [@dmx011C6]; [@dmx011C93]; [@dmx011C48]; [@dmx011C60]; [@dmx011C67]; [@dmx011C5]; [@dmx011C27]; [@dmx011C47]). Two additional patients underwent oophorectomy at ages 60 ([@dmx011C50]) and 57 ([@dmx011C93]) respectively; however, it was unclear in these two cases whether the patients had already naturally transitioned to menopause.

### Menopausal hormonal preparations {#dmx011s8d_2}

HRT commonly consisted of unopposed oestrogens (*n* = 19) ([@dmx011C10]; [@dmx011C50]; [@dmx011C77]; [@dmx011C26]; [@dmx011C1]; [@dmx011C98]; [@dmx011C42]; [@dmx011C71]; [@dmx011C44]; [@dmx011C63]; [@dmx011C70]; [@dmx011C6]; [@dmx011C93]; [@dmx011C48]; [@dmx011C60]; [@dmx011C67]; [@dmx011C5]; [@dmx011C47]) for a median duration of 6.7 years (range 3--20 years). Conjugated equine oestrogens (Premarin 1.25 mg/day or 0.625 mg/day) were frequently mentioned (*n* = 8) ([@dmx011C10]; [@dmx011C50]; [@dmx011C77]; [@dmx011C42]; [@dmx011C71]; [@dmx011C93]; [@dmx011C48]). Oestradiol implants were also implicated (*n* = 4) ([@dmx011C1]; [@dmx011C98]; [@dmx011C44]; [@dmx011C47]), as well as oestrogen injections (*n* = 1) ([@dmx011C26]). One interesting case of ureteral malignant mullerian carcinosarcoma in a 75-year-old woman was associated with 5 years of taking a phytoestrogen supplement (highly concentrated soy isoflavone) ([@dmx011C67]).

Of note, two incidences of malignancy were reported in women who had discontinued HRT several years before presentation ([@dmx011C47]). In a case series of women over 55 years old, one woman used oestrogen implants (50--100 mg every 6 months) for 14 years post hysterectomy. She had stopped this regimen for 8 years before presenting with malignancies (adenosarcoma and endometrioid adenocarcinoma). Another patient in this series was on a regimen of 50 mg oestradiol and 50 mg testosterone implants for 12 years post surgical menopause. She was not on any form of HRT for 4 years before presenting with an endometrioid adenocarcinoma.

### Presentation {#dmx011s8d_3}

Patients in these case reports/series presented with symptoms related to the site, extent, and type of malignancy. Vaginal bleeding was common (*n* = 7) ([@dmx011C50]; [@dmx011C77]; [@dmx011C1]; [@dmx011C6]; [@dmx011C93]; [@dmx011C47]; [@dmx011C96]), as was pain in the abdomen/pelvis/buttock (*n* = 11) ([@dmx011C10]; [@dmx011C71]; [@dmx011C63]; [@dmx011C70]; [@dmx011C60]; [@dmx011C67]; [@dmx011C19]; [@dmx011C47]). Masses were also frequently reported (*n* = 9) ([@dmx011C26]; [@dmx011C70]; [@dmx011C93]; [@dmx011C48]; [@dmx011C60]; [@dmx011C5]; [@dmx011C19]). Less frequent presentations included weight loss (*n* = 3) ([@dmx011C63]; [@dmx011C19]; [@dmx011C27]), constipation (*n* = 3) ([@dmx011C10]; [@dmx011C19]; [@dmx011C27]) and flank pain (*n* = 3) ([@dmx011C77]; [@dmx011C42]).

### Malignant transformation and management {#dmx011s8d_4}

Malignant transformation of endometriotic foci was commonly diagnosed using Sampson\'s ([@dmx011C85]) and Scott\'s ([@dmx011C87]) criteria. Endometrioid adenocarcinoma was by far the most commonly diagnosed HRT-associated malignancy in patients with a history of endometriosis (*n* = 18) ([@dmx011C50]; [@dmx011C77]; [@dmx011C26]; [@dmx011C1]; [@dmx011C98]; [@dmx011C44]; [@dmx011C63]; [@dmx011C70]; [@dmx011C6]; [@dmx011C93]; [@dmx011C48]; [@dmx011C5]; [@dmx011C19]; [@dmx011C27]; [@dmx011C47]). Other histological types included adenosarcoma (*n* = 2) ([@dmx011C60]; [@dmx011C47]), clear cell carcinoma (*n* = 1) ([@dmx011C10]), mullerian carcinosarcoma (*n* = 1) ([@dmx011C67]), endometrial stromal sarcoma (*n* = 1) ([@dmx011C47]) and an androgen-producing endometrioid borderline tumour (*n* = 1) ([@dmx011C71]). One interesting study reported an adenocarcinoma followed by an adenosquamous carcinoma arising in endometriotic foci 3 months later ([@dmx011C77]).

Treatments varied based on histological type, grade and stage of the tumour. In only one case it was decided to forego surgical management and treat solely with chemotherapy ([@dmx011C5]). In this case, the decision to initiate chemotherapy instead of surgery was based on her previous surgical history (two ileostomies) and poor prognosis due to advanced disease.

Adjuvant or neoadjuvant treatments in the form of chemotherapy (*n* = 9) ([@dmx011C77]; [@dmx011C98]; [@dmx011C71]; [@dmx011C6]; [@dmx011C48]; [@dmx011C19]; [@dmx011C47]), radiation (*n* = 7) ([@dmx011C10]; [@dmx011C77]; [@dmx011C26]; [@dmx011C1]; [@dmx011C63]; [@dmx011C93]; [@dmx011C19]) or progestin therapy (*n* = 4) ([@dmx011C77]; [@dmx011C1]; [@dmx011C71]) were frequently initiated. Mean follow-up was 19.4 months (range: 6 weeks to 5 years). Outcomes were generally favourable with no evidence of disease in 13 patients at follow-up ([@dmx011C10]; [@dmx011C77]; [@dmx011C98]; [@dmx011C71]; [@dmx011C44]; [@dmx011C63]; [@dmx011C70]; [@dmx011C6]; [@dmx011C93]; [@dmx011C48]; [@dmx011C60]; [@dmx011C67]). The patient treated solely with chemotherapy was alive and well at 2 years after presentation ([@dmx011C5]).

### Mortality {#dmx011s8d_5}

Although the majority of patients responded to treatment and were cured of their malignancy, three of the 25 patients diagnosed with an endometriosis-associated malignancy died as a result of their disease ([@dmx011C77]; [@dmx011C26]; [@dmx011C19]). [@dmx011C77] reported the case of a 47-year-old woman with a history of extensive pelvic endometriosis. She was on conjugated oestrogens (Premarin) 0.625 mg for 5 days every week for 4 years. She was initially diagnosed with a grade two adenocarcinoma arising from an endometriotic focus and obstructing the left ureter. Subsequently she was also diagnosed with moderately differentiated adenosquamous carcinoma arising from endometriotic foci. The patient was treated with cisplatinum and cyclophosphamide chemotherapy, but died after 11 months. In the case reported by [@dmx011C26], the patient was a 62-year-old woman with a history of severe endometriosis involving both ovaries and the rectovaginal septum. She had received intramuscular oestrogen injections for 20 years following a hysterectomy and bilateral oophorectomy. After 3 years with no treatment, she resumed another hormone substitution regimen (not specified) for hot flushes. Within a year of commencing this hormonal substitution, the patient presented with a pelvic mass diagnosed as endometrioid adenocarcinoma. About 6 weeks after tumour excision, recurrence was diagnosed and the patient died despite radiotherapy. [@dmx011C19] reported the case of a 66-year-old woman who presented with abdominal/pelvic pain and mass, alteration of general state, 10 kg weight loss, constipation and dysuria. She had used combined HRT (oestradiol and medroxyprogesterone acetate) for 11 years. After being diagnosed with extragenital endometrioid carcinoma in the vesico-uterine pouch arising from endometriosis, she was treated with surgery, chemotherapy and radiation. The patient was deceased 8 months later.

One unique case series by [@dmx011C53] identified by our search reported on larger numbers of women and thus is presented separately. They describe the management of 27 women with endometriosis-related malignancy, identified during a 7-year period (by their presentation to one of the authors, and review of pathology records). The authors include all women with endometriosis-related malignancy, rather than exclusively postmenopausal women. However, it is clear from the article that a number of participants were postmenopausal. In particular, 10 women were identified with extragonadal (non-ovarian) malignancy, and 9 of these were clearly menopausal (with either a medical history of hysterectomy/BSO, or reported as using HRT). Of these 10 women, their malignancies were histologically described as endometrioid (*n* = 5), adenosquamous (*n* = 2), papillary adenocarcinoma (*n* = 1) or adenocarcinomas not otherwise specified (*n* = 2). Within this group, six women had taken unopposed oestrogen therapy for a mean duration of 23.4 years (range 10--32 years). The authors therefore suggest that unopposed oestrogen use could be a risk factor for endometriosis-associated malignancy, especially of non-ovarian location. Treatments included surgery, chemotherapy and radiation with a 70% reported survival at follow-up (mean: 26.3 months).

Observational studies and clinical trials (6 studies) {#dmx011s8e}
-----------------------------------------------------

Only six observational studies and clinical trials were identified by our search, highlighting the paucity of higher-level evidence in this area. These studies aimed to cover a variety of clinical questions, and the evidence for these is summarized below and in Table [V](#dmx011TB5){ref-type="table"}. All assessed recurrence of endometriosis as their primary outcome. Table VQuality assessment of observational and clinical trials assessing risk of endometriosis recurrence after HRT.Quality assessmentNo of patientsEffectEvidence qualityStudiesStudy designRisk of biasInconsistencyIndirectnessImprecisionOther considerationsInterventionControlRelative (95% CI)**Comparison of HRT with no HRTHRTNo treatment**[@dmx011C56]Randomized trialSerious^[a](#dmx011tfn5){ref-type="fn"}^Not seriousNot seriousVery serious^[b](#dmx011tfn6){ref-type="fn"}^None4/115 (3.5%)0/57 (0.0%)**RR 4.50** (0.25 to 82.17)^[c](#dmx011tfn7){ref-type="fn"}^⨁◯◯◯VERY LOW[@dmx011C75]Observational studyVery serious^[d](#dmx011tfn8){ref-type="fn"}^Not seriousNot seriousVery serious^[b](#dmx011tfn6){ref-type="fn"}^None4/90 (4.4%)0/17 (0.0%)**RR 1.78** (0.10 to 31.64)^[c](#dmx011tfn7){ref-type="fn"}^⨁◯◯◯VERY LOW[@dmx011C2]Observational studySerious^[e](#dmx011tfn9){ref-type="fn"}^Not seriousNot seriousNot applicable^[f](#dmx011tfn10){ref-type="fn"}^None0/11 (0%)0/8 (0%)**Not calculable**^[g](#dmx011tfn11){ref-type="fn"}^⨁◯◯◯VERY LOW**Comparison of delayed HRT with immediate HRTDelayed HRTImmediate HRT**[@dmx011C39]Observational studyNot seriousNot seriousNot seriousNot seriousNone(\>6 weeks from surgery)7/35 (20.0%)(≤6 weeks from surgery)4/60 (6.7%)**HR 5.74** (1.31 to 25.23)^[h](#dmx011tfn12){ref-type="fn"}^⨁⨁◯◯LOW[@dmx011C7]Observational studyVery serious^[i](#dmx011tfn13){ref-type="fn"}^Not seriousNot seriousNot applicableNone(5 months from surgery)0/8 (0%)(3 months from surgery)0/5 (0%)**Not calculable**^[g](#dmx011tfn11){ref-type="fn"}^⨁◯◯◯VERY LOW**Comparison of HRT with tiboloneHRTTibolone**[@dmx011C28]Randomized trialSerious^[j](#dmx011tfn14){ref-type="fn"}^Not seriousNot seriousVery serious^[b](#dmx011tfn6){ref-type="fn"}^None4/10 (40.0%)1/11 (9.1%)**RR 4.40** (0.59 to 33.07)^[c](#dmx011tfn7){ref-type="fn"}^⨁◯◯◯VERY LOW**Comparison of oestrogen-only HRT with combined HRTOestrogen-only HRTCombined HRT (continuous and cyclical)**[@dmx011C75]Observational studyVery serious^[d](#dmx011tfn8){ref-type="fn"}^Not seriousNot seriousVery serious^[b](#dmx011tfn6){ref-type="fn"}^None4/50 (8.0%)0/40 (0.0%)**RR 7.24** (0.40 to 130.54)^[c](#dmx011tfn7){ref-type="fn"}^⨁◯◯◯VERY LOW[^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14]

Should HRT be given to women with previous endometriosis? {#dmx011s8f}
---------------------------------------------------------

Given the concerns of possible disease reactivation or malignant transformation of endometriotic foci, it is reasonable to consider whether treatment with HRT is justifiable in this group of women. However, in a field dominated by case reports and series, it is challenging to obtain information on risk. Our search identified a single RCT and two cohort studies that give some insight regarding the risk of HRT in this cohort of women. All three studies were assessed as very low quality by GRADE criteria ([@dmx011C35]).

The only RCT in this area was a single centre study from Spain, including a total of 172 women ([@dmx011C56]). All participants had a history of endometriosis and underwent BSO. Women were randomly allocated to treatment with combined HRT (50 μg oestradiol daily administered via patches and oral micronized progesterone for 14 days out of every 30 days) or no treatment. Participants were aware of their treatment allocation, although the clinician assessing them was not. In the treatment group, HRT was started 4 weeks following surgery. All women were followed up every 6 months with a clinical review, vaginal ultrasound and hormone measurements. Recurrence of endometriosis was identified either through histological confirmation, or by clinical findings (pelvic pain and/or pelvic mass) in association with pelvic ultrasound images suggestive of endometriosis. The overall absolute recurrence rate for endometriosis in this study was low at 2.3% (4/172). However, all women who experienced recurrence of endometriosis had been assigned to the HRT treatment arm (recurrence in 3.5% (4/115) of women compared to 0% (0/57) of women in the no treatment arm). The authors also suggested that the presence of residual endometrial tissue may be a possible risk factor for disease recurrence. In this cohort, the recurrence rate was 22.2% in women who had either a subtotal hysterectomy or BSO alone (2 out of 9 women). In contrast, the rate was only 1.9% (2 out of 106 women) in those who had total hysterectomy and BSO. The authors further suggest that a greater burden of disease may increase the risk of recurrence, as shown by an increased recurrence risk for women who had peritoneal involvement of greater than 3 cm, and a non-significant trend to increased recurrence with more advanced stages of endometriosis. The authors rightly noted that their study was underpowered to detect a statistically significant change in recurrence rates between the two groups of women. However, the study raises interesting possibilities for further research into the effect of disease stage and extent on recurrence rates.

One observational study included women who took postoperative HRT (of different regimens) and those who did not ([@dmx011C75]). In this retrospective, single centre cohort, the authors identified 107 women who had undergone hysterectomy and BSO for treatment of endometriosis. Women were treated with a variety of HRT regimens (total *n* = 90, taking unopposed oestrogen, continuous combined HRT, or cyclic HRT) or no treatment (*n* = 17). Recurrence was only identified in four women and all were receiving HRT, specifically unopposed oestrogen therapy. Three women had recurrent pain, and one woman had a vaginal nodule, confirmed as endometriosis on histology.

One further observational study reported on outcomes of women with deep infiltrating endometriosis and colorectal or rectovaginal disease, who underwent surgery without bowel resection ([@dmx011C2]). This retrospective comparative cohort study was conducted in Spain and included women who were operated on at one of two hospitals. Of 42 patients, 19 had a hysterectomy and BSO, whilst the remainder had conservative surgery. Of the 19 women who underwent surgical menopause, 11 were subsequently treated with HRT, comprising 1--2 years of combined oestrogen/progesterone, followed by low dose oestrogen-only HRT or tibolone, continued indefinitely. The remaining 8 women did not receive HRT. The mean follow-up was 4.3 years (standard deviation 4.5, range 1--18). During this time, no women from either group were diagnosed with recurrence of endometriosis.

Should HRT be given immediately following surgical menopause? {#dmx011s8g}
-------------------------------------------------------------

Further questions arise for women who undergo surgical menopause. If small deposits of endometriotic tissue remain following surgery, these may be triggered to proliferate by exogenous oestrogens given as HRT and increase the risk of recurrence or malignant transformation. Therefore, there may be a theoretical benefit in delaying the start of HRT, by allowing time for residual endometriotic tissue to regress before commencing exogenous oestrogen. Two retrieved articles, a retrospective cohort study ([@dmx011C39]) (GRADE: low quality) and non-comparative cohort ([@dmx011C7]) (GRADE: very low quality), attempted to investigate this question.

The retrospective cohort study ([@dmx011C39]) included women who underwent TAH with BSO, identified from the medical records of a single institution during a period of 12 years (1979--1991). Two groups of women were identified: those who commenced HRT within 6 weeks of their surgery (*n* = 60) and those who delayed starting HRT for at least 6 weeks (*n* = 35, mean time to starting HRT 71.1 weeks, range 7--520 weeks). Women who did not receive HRT were excluded. Information on symptom recurrence was obtained through the medical records or telephone follow-up, but a precise definition of recurrence was not reported. The mean duration of follow-up was 4.5 years. In unadjusted analyses, 4/60 (6.7%) women who began HRT immediately had recurrent pain, compared to 7/35 (20%) women who began HRT later on. Of note, in their adjusted analyses, in which endometriosis stage, age and postoperative adjunct medroxyprogesterone therapy were considered, starting oestrogen-replacement therapy (ERT) more than 6 weeks after surgical menopause had a hazard ratio of 5.7 for pain recurrence (95% CI; 1.3, 25.2). The authors therefore conclude that there is no increase in the risk of recurrence for women who commenced ERT immediately, as compared to those who delayed treatment.

A non-comparative cohort study ([@dmx011C7]) prospectively followed 13 women at one institution in Malaysia undergoing TAH and BSO for moderate or severe endometriosis. Patients were premenopausal at recruitment and had their endometriotic activity assessed by blood CA 125 levels taken pre-operatively and post-operatively (monthly). Eight patients received conjugated oestrogens in the form of Premarin (oral dose of 0.625 mg/day) starting 5 months post surgery, and five patients received oestrogens 3 months post surgery. Preoperative CA 125 levels were high in all 13 patients and declined to normal post surgery. Levels did not rise during the 6-month follow-up period and patients remained well and asymptomatic.

What menopausal treatments are most appropriate for women with previous endometriosis? {#dmx011s8h}
--------------------------------------------------------------------------------------

If a woman with a history of endometriosis does decide to opt for HRT, then the next decision must be to choose the most suitable preparation. Again, there is limited high-quality evidence on which to base this decision. Two studies, retrieved by our search, provide some insight into this question. The first was a RCT ([@dmx011C28]) comparing HRT using transdermal oestradiol with tibolone, and the second was an observational study ([@dmx011C75]) comparing oestrogen-only HRT with combined HRT. Both were assessed as very low quality using the GRADE system.

The RCT ([@dmx011C28]) compared HRT (*n* = 10, transdermal oestradiol 50 mg twice weekly plus cyclic medroxyprogesterone acetate 10 mg daily for women with a uterus) and tibolone (*n* = 11, 2.5 mg orally once a day) in women with residual endometriosis after bilateral oophorectomy. Patients were randomized into one of the two treatment groups and followed for 1 year. Four patients in the oestradiol group experienced moderate pelvic pain during treatment compared to only one patient in the tibolone group. Furthermore, one patient in the HRT group discontinued treatment at 8 months due to the development of dyspareunia and post-coital bleeding from a vaginal mucosal endometriotic deposit. The authors concluded that tibolone may be a safer alternative for postmenopausal women with residual endometriosis, although note that their trial was very small.

The observational cohort study ([@dmx011C75]) attempted to compare various HRT regimens in women who had undergone hysterectomy and BSO for endometriosis. The majority of women (*n* = 50) were treated with unopposed oral oestrogen. Others were prescribed either continuous combined HRT (*n* = 24) or cyclical HRT (*n* = 16). Women received either conjugated equine oestrogens or oestradiol. Finally, a small group of women received no HRT (*n* = 17) and were viewed as controls. Women were followed up for a mean duration of 3.5 years (range 0.5--18 years). Although there were no statistically significant differences between the groups, the only episodes of recurrence (*n* = 4) were found in the oestrogen-only group. One woman who suffered with recurrent symptoms whilst taking oestrogen-only HRT also had relief of her symptoms when changing to a combined preparation. The authors conclude that HRT, particularly combined oestrogen and progestin regimens, is safe for postmenopausal women with underlying endometriosis.

Discussion {#dmx011s9}
==========

In response to concerns regarding an increased risk of breast cancer raised by the Women\'s Health Initiative ([@dmx011C82]) and the Million Women Study ([@dmx011C21]), HRT usage substantially decreased ([@dmx011C38]). Nevertheless, millions of women continue to rely on hormonal preparations for menopausal symptom relief and HRT remains the most effective treatment for menopausal vasomotor symptoms and vulvar and vaginal atrophy ([@dmx011C86]). However, amongst women with a history of endometriosis, HRT may entail additional risks, and to date there are no high-quality evidence-based guidelines to guide clinical decisions.

The articles described here provide insight into the management of menopausal symptoms amongst women with a prior history of endometriosis. The case reports and series included in our review, while limited in their usefulness in assessing prevalence, indicate that recurrence of endometriosis and malignant transformations can occur in postmenopausal women. Observational studies and clinical trials have further investigated the contingent risks of different forms and timing of HRT treatments.

Recurrence {#dmx011s9a}
----------

Endometriosis is not exclusively a premenopausal disease. About 13 case reports and series found 17 cases of recurrent endometriosis in postmenopausal women taking some form of HRT. These cases included women who underwent natural and surgical menopause; however, the vast majority underwent surgical menopause, perhaps indicating more severe premenopausal disease. Similarly, [@dmx011C102] reported substantial 5-year endometriosis recurrence rates, albeit amongst premenopausal women, of 43.5% (pain) and 28% (clinical disease) for women treated with conservative surgery (preservation of the uterus and at least one ovary) ([@dmx011C102]).

In the case reports, symptoms of postmenopausal endometriosis were similar to those reported in premenopausal endometriosis ([@dmx011C64]): abnormal bleeding and pain. There are few papers describing the presentation of chronic pelvic pain (CPP) in postmenopausal women specifically. From clinical experience, symptoms are not cyclical unless a cyclical HRT preparation is used; however, pain associated with bowel and bladder function is common in postmenopausal women with CPP. Dyspareunia, especially superficially, may be associated with atrophic tissues but may also present in women using HRT with well-oestrogenized tissues. Deep dyspareunia, the more pathognomonic form of painful intercourse associated with endometriosis, is rarely described. Future research should investigate the prevalence of this symptom and whether and to what extent dyspareunia (superficial or deep) may contribute to postmenopausal sexual behaviour. Perhaps the most important difference in clinical practice, however, is the need to investigate new onset pelvic pain in a postmenopausal woman, whilst guidance on the management of CPP in reproductive age women emphasizes the need to avoid over-investigation and thus over-medicalization of the symptom when no underlying cause has previously been found (Home Page. Map of Medicine Web site. <http://www.mapofmedicine.com/>. \[Accessed January [@dmx011C40]\]). Findings from this review would suggest that investigation is needed when a postmenopausal woman is known to have had a previous diagnosis of endometriosis due to the added risk of malignant transformation.

The genitourinary system was the most common site of presentation, with many reports involving the ureter. This may represent the bias of case reports towards documenting more severe cases. Ureter involvement is a serious complication of endometriosis, capable of causing hydronephrosis and renal failure ([@dmx011C18]). It has been suggested that most cases of ureteral endometriosis in postmenopausal women are actually a result of delayed presentation with onset prior to menopause ([@dmx011C105]). However, due to a lack of clinically relevant biomarkers and sufficiently specific imaging techniques, the onset of endometriosis remains unclear ([@dmx011C58]; [@dmx011C25]).

Prognosis was generally favourable after excision of endometriotic tissue. Randomized controlled trials corroborate these findings, reporting decreased pain and symptoms after laparoscopic surgery for endometriosis, although these trials did not specifically investigate ureteric surgery ([@dmx011C24]).

In three observational studies and one randomized clinical trial ([@dmx011C7]; [@dmx011C56]; [@dmx011C75]; [@dmx011C2]), there appeared to be a small association between HRT and endometriosis recurrence, but there were no statistically significant differences between treatment and control groups. The current literature assessing risks of HRT in women with a history of endometriosis are uncertain, due to paucity of sufficiently large, high-quality studies. Current guidelines, consensus statements and recommendations acknowledge this deficit, but continue to emphasize the benefits of HRT over the undefined risks for severely symptomatic women ([@dmx011C4]; [@dmx011C43]; [@dmx011C25]). However, many women with endometriosis who undergo surgical menopause are given hormonal replacement therapy as a prophylaxis before the development of menopausal symptoms. For these women, clinicians must balance the benefits to bone ([@dmx011C14]) and cardiovascular health ([@dmx011C83]), particularly for younger patients, against the potential risks of recurrence or malignancy.

It is important to note that recurrence is possible even in the absence of HRT. There are reports of endometriosis recurrence in women not on any hormonal treatment ([@dmx011C29]; [@dmx011C9]). In these women, other risk factors such as hyperestrogenemia and obesity may play larger roles in the pathogenesis ([@dmx011C72]). Incomplete definitive surgery and residual ovarian remnants are also considered risks factor for the development of postmenopausal endometriosis ([@dmx011C23]). It remains to be confirmed whether a genetic predisposition together with environmental factors, medication, or fat distribution increase the risk of endometriosis after menopause, as has been shown for premenopausal women ([@dmx011C73],[@dmx011C74]).

Malignant transformation {#dmx011s9b}
------------------------

Our search retrieved 20 case reports and series (25 patients) of malignant transformation of endometriotic foci following HRT. Of 25 patients, 22 had undergone surgical menopause, which was not surprising given that many women had a history of severe disease with comorbidities such as leiomyomas and adenomyosis. Unopposed oestrogens were implicated in 19 patients, with conjugated equine oestrogens implicated in eight patients and oestradiol implants in four patients. Currently there are no data to indicate the absolute risk of malignant transformation in this group of women. It is likely that this is a rare outcome, but better data are urgently needed to enable women to make an informed decision about menopausal management. Fortunately, tumours arising from endometriosis are typically low grade and have a better prognosis ([@dmx011C36]); only three deaths were reported in the literature identified by our search. Mortality was noted in the two case reports with patients who had histories of severe endometriosis and complicating factors, including increased age ([@dmx011C26]) or multiple malignancies ([@dmx011C77])

Considerations regarding type and timing of HRT {#dmx011s9c}
-----------------------------------------------

Adjusting the type and timing of the treatment plan may mitigate the potential risks of HRT highlighted by our case reports and series.

### Type: oestrogen-only, combined or tibolone {#dmx011s9c_1}

Our review retrieved evidence on three main types of HRT: oestrogen-only, combined and tibolone.

A consistent theme among the case reports is the predominance of oestrogen-only HRT in women with recurrence or malignancy. The majority of case reports concerned women taking unopposed oestrogens, particularly conjugated equine oestrogens. This is not surprising given the strong association between unopposed oestrogens and endometrial cancer ([@dmx011C90]). As a result, current recommendations favour continuous combined preparations instead of unopposed oestrogens for women with a history of endometriosis, but the evidence remains sparse ([@dmx011C92]; [@dmx011C68]). We identified a single observational study that addressed this issue, including only 90 women ([@dmx011C75]). Although the only women who developed recurrent symptoms were those taking oestrogen-only HRT, the study was retrospective and unable to demonstrate statistically significant differences between the groups. The authors suggested that combined HRT preparations might be the most appropriate for women with endometriosis who are using HRT. Large, randomized trials or observational studies with appropriate statistical power are clearly needed to clarify this question. Further research is urgently needed given the increased risk of breast cancer associated with combined HRT, although it is mostly in the older age group, which has been attributed to progestins ([@dmx011C16]).

Tibolone therapy has also been associated with recurrence of endometriosis ([@dmx011C95]). One RCT included in our review considered the use of tibolone, as compared with combined HRT, but the results should be interpreted with caution given the small sample size (*n* = 21). [@dmx011C28] concluded that tibolone (which typically has an oestrogenic effect on climacteric symptoms and bone, yet a progestogenic effect on tissues) might be a safer alternative to traditional HRT in patients with residual endometriotic disease, but no statistically significant difference was seen between the groups.

Notably, one case report highlights the importance of asking patients about their use of supplements or complementary/alternative medication. Five-year use of a highly concentrated isoflavone supplement was associated with florid recurrence of endometriosis and ureteral malignant mullerian carcinosarcoma ([@dmx011C67]). This report raises further concerns over the use of phytoestrogens in postmenopausal women with a history of endometriosis ([@dmx011C22]), despite some clinical and animal literature suggesting a reduced risk of endometriosis with dietary isoflavones ([@dmx011C99]; [@dmx011C104]). Given the high prevalence of supplement use, it is important to further explore the relationship between phytoestrogens and endometriosis.

### Timing: initiation and duration {#dmx011s9c_2}

Data are also lacking on the optimal time to commence HRT following surgical menopause. We identified a retrospective study in this area, comparing immediate (within 6 weeks of surgery) to delayed (≥6 weeks following surgery) commencement of HRT ([@dmx011C39]). Although the crude incidence of recurrence was not different between the groups, increased recurrence was noted for women who delayed starting HRT after adjusting for confounders (AFS score at time of surgery, age at hysterectomy and postoperative adjunctive use of medroxyprogesterone). The authors themselves note the strong likelihood of bias in this observational study; it is probable that deferring the start of HRT would have been recommended to women felt to be at higher risk of recurrent symptoms. Additionally, we retrieved a non-comparative cohort study ([@dmx011C7]), which prospectively followed eight women who received conjugated oestrogens in the form of oral daily Premarin 5 months post surgical menopause, and five women who received oestrogens 3 months post surgical menopause. Women from both groups remained well and asymptomatic at 6-month follow-ups, yet clearly a much longer follow-up duration is necessary to be able to accurately assess risk of recurrence. The authors of this study also did not specify any symptoms or provide additional detail on patient status, and thus the evidence provided by this study was assessed as very low quality. Randomized trials are clearly needed to avoid this risk of bias, and have the potential to answer this question robustly.

Our search retrieved no studies investigating the total time for which women with histories of endometriosis should be treated. This is unfortunate given that it takes time to acquire mutations in endometriotic tissue, and thus duration of HRT therapy may have a large impact on probability of malignancy. Our systematic review also retrieved case reports of malignant transformation 4 and 8 years after stopping HRT treatment ([@dmx011C47]), indicating that hormone replacement may either still have effects years after discontinuation or that the use of HRT is only one factor in malignant transformation of endometriosis.

Conclusion {#dmx011s10}
==========

Endometriosis is not exclusively a condition of the reproductive phase. Existing guidelines in this area emphasize the lack of evidence, but suggest that women should not be denied HRT treatment simply because of a history of endometriosis ([@dmx011C4]; [@dmx011C25]). Our review indicates that women with a history of endometriosis should be carefully counselled about the possibility of disease recurrence after the menopause (Fig. [2](#dmx011F2){ref-type="fig"}). Although the absolute risk is unclear and likely to be low, women should be advised to seek help if they experience endometriosis-like symptoms, rather than suffer in silence. Furthermore, clinicians should adopt a cautious approach in cases of recurrence, keeping in mind the possibility of malignant transformation. For postmenopausal women with recurrent, treatment-resistant symptoms, consideration should be given to obtaining tissue for histology in order to exclude the possibility of malignancy, especially if other unusual or suspicious symptoms are present.

![Suggested clinical approach to postmenopausal patients with a history of endometriosis.](dmx011f02){#dmx011F2}

Although this review highlights potential risks of HRT, its substantial benefits should not be overlooked. In particular, the benefits may outweigh the costs of HRT for women with an early or surgical menopause. HRT has been shown to enhance cortical volumetric bone mineral density and compressive strength ([@dmx011C59]; [@dmx011C51]). Additionally, studies have shown a reduced risk of coronary heart disease when hormonal therapy is administered to women with early natural or surgical menopause ([@dmx011C69]). Importantly, unilateral or bilateral oophorectomy prior to the onset of natural menopause is associated with an increased risk of dementia and cognitive impairment ([@dmx011C79]); however, these risks may be reduced if HRT is administered up until the average age of natural menopause ([@dmx011C80]).

As with any woman commencing HRT, a full and frank discussion should be held about the risks and benefits of this treatment. Currently, clinicians must balance the benefits and risks of HRT, with attention to individual risk factors (age and BMI), and choose appropriate therapies directed at specific menopausal symptoms. Patients must be actively involved in the decision process, and understand our limitations as providers to quantify specific risks. Women should be advised that there are no robust data to indicate whether HRT changes the risk of disease recurrence or malignant transformation. Small studies have suggested the possibility of increased recurrence in women who take HRT, in particular unopposed oestrogen. Some authors advocate the use of combined HRT for women with a history of endometriosis, to minimize the risk of recurrence ([@dmx011C62]; [@dmx011C25]), but there are still risks with combined oestrogen-progestin hormone therapy. These include an elevated risk of breast cancer both during and post-intervention mostly in older women ([@dmx011C17]). Therefore care must be individualized, with the woman\'s personal and family history taken into account.

There are many promising areas for future research in this group of women. Our search retrieved no papers on the use of alternative selective oestrogen receptor modulators (SERMs) in postmenopausal patients with histories of endometriosis. We are aware of studies testing the gynaecologic safety of SERMS such as ospemifene and bazedoxifene, and combining these agents with oestrogens (especially bazedoxifene/conjugated oestrogens) ([@dmx011C61]). Such studies have been promising, and may represent a future alternative to conventional HRT for our cohort.

Summary {#dmx011s11}
=======

Our review highlights an important and severely under-researched area of gynaecology. The prevalence of endometriosis means that both specialists and general practitioners will inevitably encounter women with a history of this condition who are facing the dilemma of managing the menopause. Many women will have suffered years of debilitating symptoms before diagnosis, and then proceeded to undergo multiple treatments and operations in an attempt to regain some quality of life. These women deserve to have accurate, individualized and specific information about the risk of recurrence with different menopausal treatments, so that they can make an informed decision about their care.
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[^1]: TAH, total abdominal hysterectomy; SO, salpingo-oophorectomy; ERT, oestrogen-replacement therapy.

    Surgical menopause refers to procedures involving bilateral oophorectomy.

[^2]: TAH/BSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy.

[^3]: ^a^Article describes a total of 27 women with endometriosis-related malignancy; however, it is unclear how many of these women were postmenopausal. A subgroup of women with extra-ovarian disease (*n* = 10) included eight women with a history of hysterectomy and BSO, and one further woman who was taking unopposed oestrogens (therefore was presumably menopausal). For the purposes of this analysis, only these 10 women are described.

[^4]: CI, confidence interval; HR, hazard ratio; HRT, hormone replacement therapy; RR, risk ratio.

[^5]: ^a^High risk of performance bias---single blinded study, with physician unaware of treatment allocation, but with access to hormone results (which would have indicated treatment with HRT or not). High risk of detection bias, as assessment for recurrence was only carried out if the clinician felt this was warranted, which may have been influenced by the participant (who was not blind to treatment allocation).

[^6]: ^b^Very wide CI for RR.

[^7]: ^c^RR calculated by the authors using Review Manager (RevMan) \[Computer program\]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, [@dmx011C78].

[^8]: ^d^High risk of selection bias as unclear why women were allocated to different HRT regimens (or no HRT). High risk of detection bias, as researchers would have been aware of the woman\'s HRT status when assessing presence of recurrence (by reviewing medical records).

[^9]: ^e^Risk of detection bias, as criteria for designating recurrence are not clearly stated.

[^10]: ^f^Not applicable as odds ratio and CI cannot be calculated.

[^11]: ^g^No events in either group, therefore odds ratio not calculable.

[^12]: ^h^HR adjusted for stage of endometriosis, age at time of hysterectomy and postoperative adjunct medroxyprogesterone therapy.

[^13]: ^i^High risk of selection bias (unclear why some women started HRT after 3 months and some after 5 months), and high risk of detection bias (recurrence was only based on CA 125 levels).

[^14]: ^j^No description of blinding for the trial, and no scoring system is reported for pain, therefore risk of detection bias.
